Industry Relations Council
8735 W. Higgins Road Suite 300 Chicago, IL 60631
Tel: (847)375-6340 Email: info@itns.org

Search our Site

Industry Relations Council (IRC)

The ITNS Industry Relations Council is available to organizations that support the goals and mission of ITNS and provide products or services used in the area of transplantation. Membership is for one year. It is a nonvoting membership with benefits extended to a single corporate-designated representative. Membership is available at an associate or executive level. Read about the benefits of joining the IRC and apply today.

 

Executive Level

 

 AstellasTransplant RGB

 

Astellas Pharma US, Inc.
1 Astellas Way
Northbrook, IL 60062

Astellas Pharma US, Inc. is the headquarters for the Americas for Astellas Pharma (Toyko). Astellas is a pharmaceutical company dedicated to improving the health of people around the world by providing innovative and reliable products in the areas of cardiology, dermatology, infectious disease, oncology, transplant and urology.


Audentes LOGO

Audentes Therapeutics is a clinical stage biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases. We are a focused, experienced and passionate team committed to forging strong, global relationships with the patient, research and medical communities.

www.audentestx.com

Clinical Assessment Study in Crigler-Najjar Syndrome (LUSTRO)
https://clinicaltrials.gov/ct2/show/NCT03078881?term=audentes+therapeutics&cond=Crigler-Najjar+Syndrome&rank=2

Gene Transfer Clinical Study in Crigler-Najjar Syndrome (VALENS)
https://clinicaltrials.gov/ct2/show/NCT03223194?term=audentes+therapeutics&cond=Crigler-Najjar+Syndrome&rank=1

 

Veloxis logo RGB 300dpi

 

Veloxis Pharmaceuticals
1001 Winstead Drive, 3rd floor, Suite 310
Cary, North Carolina 27513
www.veloxis.com

Veloxis Pharmaceuticals (Veloxis) is a specialty pharmaceutical company focused on the development and commercialization of a novel product for the prevention of organ rejection in kidney transplant patients. All clinical studies including two Phase III trials, have successfully been completed and a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) in December 2013 seeking approval for the marketing and sale. Veloxis is commited to ensuring access to ENVARSUS XR regardless of a patient's insurance or financial situation. Patient Financial Support Resources

 

Vyera

Vyera Pharmaceuticals, LLC (www.vyera.com) is committed to developing and commercializing treatments that address serious and neglected diseases with high unmet needs. One of those neglected diseases is toxoplasmosis. Toxoplasmosis has been identified as one of the five neglected parasitic infections in the US by the Centers for Disease Control and Prevention (CDC). The T. gondii parasite responsible for toxoplasmosis can be found in over 60 million individuals in the US. Immunocompromised individuals, such as transplant recipients, are at risk for acute toxoplasmosis. For information on treatment options and financial assistance programs, visit www.vyera.com. ©